Notified Body Selection Advice

Sam Lazzara
Resume
LinkedIn Profile 
Documents
Services
Schedule Call 



+1 510 397 9739
sam@lazzara.net

 Related Posts
Notified Body Short List 
Notified Body Sleuthing


Suggested Screening Questions
- Will my QS lead auditor also be my lead Technical File (CE) project manager/reviewer?
- Are any of your auditors contractors (vs. employees)?
- Who will be my QS lead auditor? Can you provide their CV (or bio)? May I speak to him/her?
- Who will be my CE Technical File lead auditor? Can you provide their CV (or bio)? May I speak to him/her?
- Is your CE lead auditor a project manager who "subcontracts" the review of the various Tech File subjects, or do they personally perform the detailed technical reviews? If the former, who else is on the review team?
- Who is our lead reviewer for clinical evaluation data? Employee/contractor? Practicing physician? Has enough time? What is their process?
- Where do my auditors live? USA? Europe? Travel costs extra or built in?
- What is your process for secondary review of audit reports submitted by auditors? What is turn time? (see Note 1)
- How often are surveillance audits? (expect annual, dread semi-annual)
- What is the process for review/approval of Change Notifications? What is the cost? Turn time?
- What if I don't like my lead auditors down the road?

Questions for Candidate Auditors (see Note 2)
- Do you enjoy your work? Are you burned out?
- What types of products do you like to work on?
- Do you agree with our assessment of the device classification per the Directive? (tell them intended use, Rule #, classification)
- What is the relationship between your work and the work of the "other" lead auditor? Good reasons to communicate with each other? Or are you completely independent.
- For single QS/CE auditors: Are there ways to leverage your intimate knowledge of our QS to reduce the need for Change Notifications down the road?
- Clinical Evaluation: Explain how clinical evaluation data is reviewed. What should we be looking out for?
- Explain how the secondary review process works at headquarters for your audit reports. How long does it take?

Note 1 - DEKRA historically has had a "peer review" followed by certification management review. Everyone will minimally have certification management review. Turn times can vary depending on work load and resources of each NB.
Note 2 - You are not just hiring a NB; you are hiring your lead auditors and perhaps a team of reviewers. You may be able to shop around for auditors within a given NB but you may end up liking the one who lives 9 time zones away (communication more challenging, travel costs greater).

Other Points To Consider / Reminders
  • Registration Audit Timeliness
    - If scheduling registration audit today, how long into the future will the audit be scheduled?
    -     Is this consistent with when your company will be ready for audit?

  • Interview Pre-Assigned Quality System Lead Auditor
  • Interview Pre-Assigned Technical File Lead Reviewer
  • Discuss CE Marking Pathway
    - Full QA System? (typical, recommended)
    - Agree on device classification
    - Clinical Evaluation Plan (literature, clinical investigation, combined)
  • Direct Costs (prepare comparison spreadsheet)
    - QMS Registration Audit Fee (Goal: EN ISO 13485 and MDD Annex II.3 certificate)
    - Technical File Review/Approval Fee (Goal: CE Certificate for product category)
    - QMS Surveillance Audit Fee
    - QMS Renewal Audit Fee (typically every 3 years after registration)
    - Fee Structure, Auditor Day Rate, Certificate Fees, etc.
    - QMS Surveillance Audit frequency? (typically 2 per cycle)

Resource
The Long List - European MDD NBs (qualified to serve as NBs under the Medical Device Directive 93/42/EEC)
Sam's Short List - Canada recognized registrars who are also European NBs (dealing with Canada demonstrates commitment)
Sam Lazzara
Resume
LinkedIn Profile 
Documents
Services
Schedule Call 



+1 510 397 9739
sam@lazzara.net

Popular posts from this blog

State of the Art

Sam Lazzara Resume LinkedIn Profile   Documents Services Schedule Call   +1 510 397 9739 sam@lazzara.net ISO 13485 requires the control of "documents of external origin" such as regulations, standards and guidelines that impact the quality management system (QMS). Changes to these external documents must be identified and appropriate actions taken to maintain "state of the art" medical devices. For example, Essential Requirement 2 of the European Medical Device Directive states: "The solutions adopted by the manufacturer for the design and construction of the devices must conform to safety principles, taking account of the generally acknowledged state of the art." Keeping up to date with evolving international regulations, standards and guidelines is always a challenge. It is one thing to become aware of revised documents; it is something else to determine the impact of the revisions on your QMS and devices. Regulations, Standards, Guidan...
Read more

ISO 13485:2016 Quality System Process Risk Management

Image
I SO 13485:2016 has a broader view of risk management than in the past. Risks are to be considered in terms of the impact on medical device safety and performance, and in terms of meeting regulatory requirements. For managing quality system process risks, rather than adding a Risk section to each Standard Operating Procedure (SOP) as some have suggested, I added a new section to my Quality Manual to address risks for each quality system process, i.e. each SOP. The front end of my new Quality Manual risk section is shown below.  A row is included in the table for each SOP. Since my Quality Manual already lists the SOPs, this makes sense to me. And by having all of the risk assessment and control information in this single document, it seems easier to manage than sprinkling risk assessment/control info into each SOP.  Sam Lazzara Resume LinkedIn Profile Documents Services
Read more

EN ISO 14971:2012 Impact Assessment

Sam Lazzara Resume LinkedIn Profile   Documents Services Schedule Call   +1 510 397 9739 sam@lazzara.net Link to Sam Lazzara's EN ISO 14971:2012 Flow Chart  Still trying to figure out what to do about EN ISO 14971:2012? The ASQ Biomedical Division just published an article I wrote called Risky Business - Demystifying EN ISO 14971:2012 . To view the article, go here . Sam Lazzara Resume LinkedIn Profile   Documents Services Schedule Call   +1 510 397 9739 sam@lazzara.net Summary EN ISO 14971:2012 became a European harmonized standard on August 30, 2012. The normative content is still in accordance with ISO 14791:2007. However, the relationship between ISO 14971 and the European Directives has changed as described in Annex ZA, ZB and ZC. Compliance with the normative clauses in ISO 14971 does not ensure conformity with the Essential Requirements (ERs) of the Directives. The Z Annexes list “content deviations” between ISO 14...
Read more